Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Alligator Bioscience

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology

              Contact the Supplier

              Lead Product(s): Mitazalimab,SCO-101

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Scandion Oncology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 04, 2020

              Details:

              The two companies will explore the anti-tumor effect of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an add-on to chemotherapy in preclinical tumor models that have been shown to be resistant to chemotherapy.

              Alligator Bioscience

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received

              Contact the Supplier

              Lead Product(s): Immune-activating antibody

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Biotheus

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 01, 2020

              Details:

              The license agreement includes exclusive rights to an immune-activating antibody directed against a receptor within the TNFR-SF, a collective name for a number of target molecules with similar functions, and applies to the China, Hong Kong, Taiwan and Macau markets.

              BioInvent

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              BioInvent Signs Manufacturing Agreement With US Cell Therapy Company

              Contact the Supplier

              Lead Product(s): Antibodies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 30, 2020

              Details:

              The agreement, for an undisclosed amount, includes process development and conjugation of two antibodies in BioInvent's development labs with work expected to start in May 2020.

              PharmaCompass__DigitalAd